U.S. stocks saw a boost on Wednesday following the Treasury Department's announcement that it would more than double its government debt repurchases. This move caused long-dated Treasury yields to fall sharply, with the 10-year note closing down 5.7 basis points to 4.647% and the 30-year bond tumbling 9 basis points to 5.196%. The increased buyback operations, targeting the 10- to 20-year and 20- to 30-year portions of the market, will raise the maximum size per operation from $2 billion to at least $4 billion, effective from September 9 through November 4.
The Treasury's decision aimed to provide greater liquidity in longer-dated nominal sectors, which had experienced a "buyers' strike" since late June. The announcement led to a market shift as participants reduced exposure to long-dated interest-rate risk and moved towards risk assets. This action is seen as an attempt to steady the bond market, although some analysts, like Mohamed El-Erian, suggest it's more about "yield curve control" and has limited impact relative to net issuance. Others, like RSM's chief economist Joe Brusuelas, expressed concern that artificially suppressing yields could complicate the Federal Reserve's inflation control efforts.
Adding to the market's dynamics, Moderna shares surged over 91% after interim results showed its experimental cancer vaccine, developed with Merck's Keytruda, met both primary goals in a late-stage melanoma trial. Merck shares also climbed more than 8%. This significant biotech news contributed to a broader uplift in the healthcare and biotechnology sectors, diverting attention from a previous technology sector sell-off. The combination of falling Treasury yields and strong biotech news helped major U.S. stock indices, with the S&P 500 climbing 0.2%, the Dow Jones Industrial Average adding 119 points (0.2%), and the Nasdaq Composite ticking 0.2% higher.
